# A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Source: https://onco.cc/trials/nct05886920/  
OnCo record `nct05886920` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of D3S-002 in advanced solid tumours, run by D3 Bio (Wuxi) Co., Ltd, now recruiting.

## Summary

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations is a phase 1/2 interventional study registered as NCT05886920 by D3 Bio (Wuxi) Co., Ltd, with 67 participants planned, started 2023-07-10 and due to reach its primary completion in 2028-08. Interventions recorded: D3S-002 and D3S-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05886920
- Phase: 1/2
- Setting: A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
- Sponsor: D3 Bio (Wuxi) Co., Ltd
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT05886920: https://clinicaltrials.gov/study/NCT05886920

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05886920.json